Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 5,201 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 5,201 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87. Following the sale, the insider now owns 135,483 shares in the company, valued at approximately $22,472,565.21. This trade represents a 3.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22.

Natera Stock Up 0.4 %

Natera stock opened at $176.92 on Monday. The stock has a market cap of $23.36 billion, a PE ratio of -100.52 and a beta of 1.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a fifty day moving average of $166.89 and a 200 day moving average of $138.50. Natera, Inc. has a one year low of $64.74 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.95) EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Canaccord Genuity Group upped their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Institutional Investors Weigh In On Natera

Hedge funds have recently modified their holdings of the business. Principal Securities Inc. raised its holdings in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. Gladstone Institutional Advisory LLC increased its position in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares in the last quarter. Silver Oak Securities Incorporated raised its stake in shares of Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares during the period. Covestor Ltd lifted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.